Plasma cell neoplasm

Researchers are testing a new type of immune cell therapy called CS1-targeted CAR-T in adults with multiple myeloma that has come back or stopped responding to treatment. The study enrolls about 10 participants who have already received several lines of therapy. Doctors collect a…

This early-phase trial tests a new type of immunotherapy called CD70 CAR T cells in people with lymphoma, myeloma, and certain solid tumors (like kidney cancer and sarcomas) that have come back or not responded to standard treatments. The immune cells are modified in the lab to r…

This trial tests whether adding a protein called CYT107 to the standard treatment for multiple myeloma helps the immune system recover faster after a stem cell transplant. The standard treatment includes a chemotherapy drug called melphalan and the transplant itself. Researchers …

This phase 2 trial is testing whether adding the targeted drug belantamab mafodotin before and after a stem cell transplant can help people with multiple myeloma achieve deeper remission. About 41 participants will receive the drug alongside standard treatments. The main goal is …

This study looks at whether people with plasma cell disorders can safely recover from an autologous stem cell transplant at home instead of in the hospital. Researchers want to see if home recovery is practical, reduces infections, and keeps patients satisfied. About 91 adults ag…

This study is testing a new drug called belantamab mafodotin when added to three standard chemotherapy drugs (carfilzomib, lenalidomide, and dexamethasone) for people with multiple myeloma, a type of blood cancer. The goal is to find the safest dose and see if this combination ca…

This study tests a daily oral drug called nemtabrutinib (ARQ 531) in 190 people with blood cancers like lymphoma or leukemia that have come back or not responded to prior treatment. The goal is to find a safe dose and see if the drug can shrink tumors. It is an early-phase trial,…

This study tests a stem cell transplant from a matched unrelated donor for people with advanced blood cancers or blood disorders. Patients get chemotherapy and radiation before the transplant to prepare their body, then take drugs to prevent the donor cells from attacking their o…

This phase 2 trial is testing a drug called elranatamab in 187 people with multiple myeloma whose cancer has not responded to at least three other types of treatment. The drug works by helping the body's immune cells attack the cancer cells. The main goal is to see how many patie…

This phase 2 trial tests a new way of giving chemotherapy to people with high-risk multiple myeloma who have already had some treatment. Instead of high doses with long breaks, researchers give lower doses in shorter cycles to prevent cancer cells from regrowing. The goal is to i…

This study tests a new way to give a drug called isatuximab as a quick shot under the skin, instead of a long IV drip, for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. The shot is combined with three standard chemotherapy drugs. The goal is…

This study tests a combination of four drugs (daratumumab, carfilzomib, lenalidomide, and dexamethasone) as the first treatment for people newly diagnosed with multiple myeloma. The goal is to see how many patients achieve a very deep response, including no detectable cancer cell…

This study tests an experimental drug called iopofosine I 131 in people with certain blood cancers (like Waldenstrom macroglobulinemia, multiple myeloma, and lymphomas) that have come back or not responded to standard treatments. The drug delivers radiation directly to cancer cel…

This early-phase trial tests a cancer vaccine (PVX-410) combined with two drugs (citarinostat and lenalidomide) in 19 people with smoldering multiple myeloma, a pre-cancer condition. The goal is to see if the combination is safe and can trigger an immune response against myeloma …

This early-phase study tests experimental cell therapies in 40 adults with relapsed and refractory multiple myeloma who have tried at least three prior treatments. The main goal is to check safety and find the right dose. While not a cure, it aims to control the disease and may l…

This phase 3 trial is testing whether adding the drug isatuximab to a standard combination of lenalidomide and dexamethasone, with or without bortezomib, can improve outcomes for newly diagnosed multiple myeloma patients aged 65 to 79 who are not eligible for a stem cell transpla…

This study looked at 729 people with newly diagnosed multiple myeloma, aged up to 65. It compared a standard drug combination (lenalidomide, bortezomib, and dexamethasone) to the same drugs plus a stem cell transplant using the patient's own cells. The goal was to see if the tran…

This study tests a new type of immune therapy for people with certain blood cancers (CLL, lymphoma, or multiple myeloma) that have come back or not responded to treatment. Researchers take a patient's own T cells, add a special receptor that targets a protein called kappa on canc…

This trial is testing a new imaging tracer called FLT, which is used with a PET scan to measure how fast tumors are growing. The study includes people with various cancers or those awaiting a biopsy for a suspicious mass. The goal is to see if FLT PET imaging can help find and di…

This study collects bone marrow and blood samples, along with medical history, from people with multiple myeloma, Waldenstrom macroglobulinemia, and related disorders. The samples are stored in a tissue bank for future research to understand what causes these cancers, how they pr…

This study uses artificial intelligence to analyze the shape of individual myeloma cells from bone marrow samples. The goal is to predict genetic abnormalities (called FISH abnormalities) without relying on subjective human review. If it works, this AI method could make genetic t…

This early-phase study tests a radioactive imaging drug called 124I-PUH71 in 63 people with non-Hodgkin's lymphoma, myeloma, or solid tumors. The goal is to see how the drug travels through the body and collects in tumors, and how long it stays in the blood. This is not a treatme…